Search This Blog

Thursday, February 7, 2019

Amag Pharmaceuticals reports Q4 EPS (64c), consensus ($1.09)

Reports Q4 revenue $88.1M, consensus $98.92M. In the fourth quarter of 2018, sales of Makena totaled $46.9 million, compared with $100.4 million in the same period last year; sales of Feraheme and MuGard increased 33% to $35.3 million, compared with $26.6 million in the same period last year; and sales of Intrarosa totaled $5.9 million, compared with $1.5 million in the same period last year.

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.